Publications 2012

  1. Lim PL, Zhou J, Ditangco RA, Law MG, Sirisanthana T, Kumarasamy N, Chen YM, Phanuphak P, Lee CK, Saphonn V, Oka S, Zhang F, Choi JY, Pujari S, Kamaru lzaman A, Li PC, Merati TP, Yunihastuti E, Messerschmidt L, Sungkanuparph S; TREAT Asia HIV Observational Database. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. J Int AIDS Soc. 2012 Jan 26;15(1):1. doi: 10.1186/1758-2652-15-1.
  2. Ramautarsing RA, van der Lugt J, Gorowara M, Wongsabut J, Khongpetch C, Phanuphak P, Ananworanich J, Lange JMA, Burger DM, Ruxrungtham K, Avihingsanon A. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg BID. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):55-8. doi: 10.1097/QAI.0b013e31823ba736.
  3. Hamers RL, Oyomopito R, Kityo C, Phanuphak P, Siwale M, Sungkanuparph S, Conradie F, Kumarasamy N, Botes ME, Sirisanthana T, Abdallah S, Li PC, Ngorima N, Kantipong P, Osibogun A, Lee CK, Stevens WS, Kamarulzaman A, Derdelinckx I, Chen YM, Schuurman R, Vugt MV, Rinke de Wit TF; on behalf of the PharmAccess African (PASER) and TREAT Asia (TASER) Studies to Evaluate Resistance. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance–HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2012 Feb;41(1):43-54. doi: 10.1093/ije/dyq192. Epub 2010 Nov 10.
  4. Sitcharungsi R, Ananworanich J, Vilaiyuk S, Apornpong T, Bunupuradah T, Pornvoranunt A, Nouanthong P, Phasomsap C, Khupulsup K, Pancharoen C, Puthanakit T, Shearer WT, Benjaponpitak S; on behalf of the HIV-NAT 108 Study Group. Nephelometry determined serum immunoglobulin isotypes in healthy Thai children aged 2-15 years. Microbiol Immunol. 2012 Feb;56(2):117-22. doi: 10.1111/j.1348-0421.2011.00413.x.
  5. Kerr SJ, Avihingsanon A, Pucharoen O, Chetcho­tisakd P, Ubolyam S, Ruxrungtham K, Cooper DA, Phanuphak P and Duncombe C. Assessing adherence in Thai patients taking HAART. Int J STD AIDS. 2012 Mar;23(3):160-5. doi: 10.1258/ijsa.2009.009152.
  6. Avihingsanon A, Matthews GV, Lewin SR, Marks P, Sasadeusz J, Cooper DA, Bowden S, SLocarnini, DoreGJ and Ruxrungtham K. Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand. AIDS Res Ther. 2012 Mar 9;9(1):6. doi: 10.1186/1742-6405-9-6.
  7. Khongphatthanayothin M, Avihingsanon A, Teeratakulpisarn N, Phanuphak N, Buajoom R, Suwanmala P, Phanuphak P. Feasibility and Efficacy of INH prophylaxis for latent tuberculosis in HIV infected Patients in Thailand. AIDS Res Hum Retroviruses. 2012 Mar;28(3):270-5. doi: 10.1089/aid.2011.0041. Epub 2011 Sep 7.
  8. Clarke A, Hsu D, Kerr SJ, Ramautarsing R, Ohata pJ, Landolt NK, Avihingsanon A, Maeka-nantawat W, Puthanakit T, Bunupuradah T, Prasitsuebsai W, Ananworanich J, Ruxrungtham K. The 15th Bangkok International Symposium on HIV Medicine. Future virology. 2012 Mar 29;7(4):341-344.
  9. Avihingsanon A, Ruxrungtham K, Katner H, Jean Guittari C, Walmsley S. Impact of baseline virologic, immunologic, and demographic characteristics on virologic responses in the gemini study. HIV Clin Trials. 2012 Mar-Apr;13(2):111-7. doi: 10.1310/hct1302-111.
  10. Winston A, Puls R, Kerr SJ, Duncombe C, Li PCK, Gill JM, Taylor-Robinson SD, Emery S, Cooper DA for the ALTAIR Study Group. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. HIV Med. 2012 Apr;13(4):245-51. doi: 10.1111/j.1468-1293.2011.00962.x. Epub 2011 Dec 12.
  11. Ananworanich J, Gorowara M, Avihingsanon A, Kerr SJ, van Heesch N, Khongpetch C, Uanithirat A, Hill A, Ruxrungtham K, Burger DM; HIV-NAT 127 Study Team. Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy. Antimicrob Agents Chemother. 2012 Apr;56(4):1892-8. doi: 10.1128/AAC.05694-11. Epub 2012 Jan 17.
  12. Wilkin A, Pozniak AL, Morales-Ramirez J, Steyn D, Santoscoy M, Grinsztejn B, Ruxrungtham K, Vanveggel S, Termini R, Boven K. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC 278) in HIV type-1 infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012 May;28(5):437-46. doi: 10.1089/AID.2011.0050. Epub 2011 Oct 17.
  13. Le Nguyen H, Pitakpolrat P, Sirivichayakul S, Delaugerre C, Ruxrungtham K. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand. J Med Virol. 2012 May;84(5):713-20. doi: 10.1002/jmv.23235.
  14. Puthanakit T, Jourdain G, Suntarattiwong P, Chokephaibulkit K, Siangphoe U, Suwanlerk T, Prasitsuebsai W, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Waranawat N, Ananworanich J on behalf of the HIV-NAT 086 study team. High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting. AIDS Res Ther. 2012 Jun 18;9(1):20. doi: 10.1186/1742-6405-9-20.
  15. Boonyanurak P, Bunupuradah T, Wilawan K, Loeanyod A, Thongpaeng P, Chatvong D, Sophonphan J, Saeloo S, Ananworanich J, Chaithongwongwatthana S. Age at menopause and menopause-related symptoms in human immunodeficiency virus-infected Thai women. Menopause. 2012 Jul;19(7):820-4. doi: 10.1097/gme.0b013e31824cfc0f.
  16. Hsu DC, Zaunders JJ, Plit M, Leeman C, Ip S, Iampornsin T, Pett SL, Bailey M, Amin J, Ubolyam S, Avihingsanon A, Ananworanich J, Ruxrungtham K, Cooper DA, Kelleher AD. A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays. Tuberculosis (Edinb). 2012 Jul;92(4):321-7. doi: 10.1016/ Epub 2012 Apr 26.
  17. Bunupuradah B, Ubolyam S, Hansudewechakul R, Kosalaraksa P, Ngampiyaskul C, Kanjanavanit S, Wongsawat J, Luesomboon W, Pinyakorn S, Kerr S, Ananworanich J, Chomtho S, van der Lugt J, Luplertlop N, Ruxrungtham K, Puthanakit T on behalf of the PREDICT study group. Correlation of selenium and zinc levels to antiretroviral treatment outcomes in Thai HIV-infected children without severe HIV symptoms. Eur J Clin Nutr. 2012 Aug;66(8):900-5. doi: 10.1038/ejcn.2012.57. Epub 2012 Jun 20.
  18. Bunupuradah T, Pinyakorn S, Puthanakit T. Prevalence of selenium deficiency in Thai HIV-infected children without severe HIV symptoms. Eur J Clin Nutr. 2012 Aug;66(8):900-5. doi: 10.1038/ejcn.2012.57. Epub 2012 Jun 20.
  19. Praditpornsilpa K, Avihingsanon A, Chaiwatanarat T, Chaiyahong P, Wongsabut J, Ubolyam S, Chulakadabba A, Avihingsanon Y, Ruxrungtham K, Tunsanga K, Eiam-Ong S, Phanuphak P. Comparisons between validated estimated glomerular filtration rate (GFR) equations and isotopic GFR in HIV patients. AIDS. 2012 Sep 10;26(14):1781-8. doi: 10.1097/QAD.0b013e328356480d.
  20. Aurpibul L, Lumbiganon P, Kolasaraksa P, Hansudewechakul R, Sa-Nguanmoo P, Taeprasert P, Bunupuradah T, Pooworawan Y, Sirisanthana V, Puthanakit T. HIV and Hepatitis B Co-infection among Perinatally HIVinfected Thai Adolescents. Pediatr Infect Dis J. 2012 Sep;31(9):943-7.
  21. Koken JA, Naar-King S, Umasa S, Parsons JT, Saengcharnchai P, Phanuphak P, Rongkavilit C. A Cross-Cultural Three-Step Process Model for Assessing Motivational Interviewing Treatment Fidelity in Thailand. Health Educ Behav. 2012 Oct;39(5):574-82. doi: 10.1177/1090198111423679. Epub 2012 Jan 6.
  22. Avihingsanon A, van der Lugt J, Singphore U, Gorowara M, Boyd M, Ananworanich J, Phanuphak P, Burger D, Ruxrungtham K. Pharmacokinetics and 48 Week Efficacy of Adjusted Dose Indinavir/Ritonavir in Rifampicin-Treated HIV/Tuberculosis-Coinfected Patients: A Pilot Study. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1170-6. Epub 2012 Mar 6.
  23. Permpalung N, Putcharoen O, Avihingsanon A and Ruxrungtham K. Treatment of HIV infection with once-daily regimens. Expert Opin Pharmacother. 2012 Nov;13(16):2301-17. doi: 10.1517/14656566.2012.729040. Epub 2012 Oct 8.
  24. Puthanakit T, Saphonn V, Ananworanich J, Kosalaraksa P, Hansudewechakul R, Vibol U, Kerr SJ, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Ngo-Giang-Huong N, Chettra K, Cheunyam T, Suwarnlerk T, Ubolyam S, Shearer WT, Paul R, Mofenson LM, Fox L, Law MG, Cooper DA, Phanuphak P, Vun MC, Ruxrungtham K; PREDICT Study Group. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis. 2012 Dec;12(12):933-41. doi: 10.1016/S1473-3099(12)70242-6. Epub 2012 Oct 9.
  25. Bunupuradah T, Chetchotisakd P, Jirajariyavej S, Valcour V, Bowonwattanuwong C, Munsakul W, Klinbuayaem V, Prasithsirikul W, Sophonphan J, Mahanontharit A, Hirschel B, Bhakeecheep S, Ruxrungtham K, Ananworanich J on behalf of HIV STAR study group. Neurocognitive Impairment in Patients Randomized to Second-line Lopinavir/ ritonavir-based Antiretroviral Therapy vs. Lopinavir/ ritonavir Monotherapy. J Neurovirol. 2012 Dec;18(6):479-87. doi: 10.1007/s13365-012-0127-9. Epub 2012 Sep 20.
  26. Puthanakit T, Saksawad R, Bunupuradah T, Wittawatmongkol O, Chuanjaroen T, Ubolyam S, Chaiwatanarat T, Nakavachara P, Maleesatharn A, Chokephaibulkit K. Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):477-83. doi: 10.1097/QAI.0b013e31826ea89b.
  27. Kosalaraksa P, Bunupuradah T, Vonthanak S, Wiangnon S, Hansudewechakul R, Vibol U, Kanchanawanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Lumbiganon P, Sopa B, Apornpong T, Chuenyam T, Cooper DA, Ruxrungtham K, Ananworanich J, Puthanakit T. Prevalence of anemia and underlying iron status in naive antiretroviral therapy HIV-infected children with moderate immune suppression. AIDS Res Hum Retroviruses. 2012 Dec;28(12):1679-86. doi: 10.1089/AID.2011.0373. Epub 2012 Jul 25.
  28. Clarke A, Kerr S, Honeybrook A, Cooper DA, Avihingsanon A, Duncombe C, Phanuphak P, Ruxrungtham K, Ananworanich J and Kaldor J. Adherence and Risk Behavior in Patients with HIV infection receiving Antiretroviral Therapy in Bangkok. Open Virol J. 2012;6:23-8. doi: 10.2174/1874357901206010023. Epub 2012 Feb 24.
  29. Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; the HIV STAR Study Group. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Antivir Ther. 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2.
  30. Maek-a-nantawat W, Avihingsanon A, and Ohata PJ. Challenges in treatment and care for viral hepatitis in co-infected individuals with HIV in a resource-limited settings. AIDS Res Treat. 2012;2012:948059. doi: 10.1155/2012/948059. Epub 2012 Mar 26.
  31. Nguyen HL, Ruxrungtham K, Delaugerre C. Genetic Barrier to the Development of Resistance to Integrase Inhibitors in HIV-1 Subtypes CRF01_AE and B. Intervirology. 2012;55(4):287-95. doi: 10.1159/000336658. Epub 2012 Mar 23.
  32. Zhou J, Tanuma J, Chaiwarith R, Lee CK, Law MG, Kumarasamy N, Phanuphak P, Chen YM, Kiertiburanakul S, Zhang F, Vonthanak S, Ditangco R, Pujari S, Choi JY, Parwati Merati T, Yunihastuti E, Li PC, Kamarulzaman A, Nguyen VK, Thuy Pham TT, Lim PL. Loss to Followup in HIV-Infected Patients from Asia-Pacific Region: Results from TAHOD. AIDS Res Treat. 2012;2012:375217. doi: 10.1155/2012/375217. Epub 2012 Feb 22.
  33. Klinklom A, Puthanakit T, Gorowara M, Phasomsap C, Kerr S, Sriheara C, Ananworanich J, Burger D, Ruxrungtham K and Pancharoen C. Low Dose of Lopinavir/ritonavir Tablet Achieves Adequate Pharmacokinetic Parameters in HIV-Infected Thai Adolescents. Antiviral Therapy. Antivir Ther. 2012;17(2):283-9. doi: 10.3851/IMP1958. Epub 2011 Nov 10.
  34. Rungsiyanont S, Vacharotayangul P, Lam-Ubol A, Ananworanich J, Phanuphak P, Phanuphak N. Perceived dental needs and attitudes toward dental treatments in HIV-infected Thais. AIDS Care. 2012;24(12):1584-90. doi: 10.1080/09540121.2012.663884. Epub 2012 Mar 20.
  35. Chokephaibulkit K, Prasitsuebsai W, Wittawatmongkol O, Gorowara M, Phongsamart W, Sophonphan J, Kerr SJ, Vanprapar N, Puthanakit T, Pasomsap C, Suwanlerk T, Sekar V, Burger D, Ananworanich J on behalf of the HIV-NAT 113 Pharmacokinetic Study Group. Pharmacokinetics of darunavir/ritonavir in Asian HIV-1 infected children aged ≥7 years. Antivir Ther. 2012;17(7):1263-9. doi: 10.3851/IMP2347. Epub 2012 Sep 6.
  36. Bunupuradah T, Puthanakit T, Kosalaraksa P, Kerr SJ, Kariminia A, Hansudewechakul R, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Chuenyam T, Saphonn V, Vun M C, Vibol U, Vannary B, Ruxrungtham K, Ananworanich J and on behalf of the PREDICT study group. Poor quality of life among untreated Thai and Cambodian children without severe HIV symptoms. AIDS Care. 2012;24(1):30-8. doi: 10.1080/09540121.2011.592815. Epub 2011 Jul 21.
  37. Landolt NK, Phanuphak N, Pinyakorn S, Lakhonphon S, Khongpetch C, Chaithongwongwatthana S, Ananworanich J. Sexual life, options for contraception and intention for conception in HIV-positive people on successful antiretroviral therapy in Thailand. AIDS Care. 2012;24(7):897-904. doi: 10.1080/09540121.2011.648161. Epub 2012 Jan 31.